Lobeglitazone/metformin - Chong Kun Dang

Drug Profile

Lobeglitazone/metformin - Chong Kun Dang

Alternative Names: CKD 395; Lobeglitazone sulfate/metformin hydrochloride - Chong Kun Dang

Latest Information Update: 27 Jan 2016

Price : $50

At a glance

  • Originator Chong Kun Dang
  • Class Antihyperglycaemics; Biguanides; Piperidines; Small molecules; Thiazolidinediones
  • Mechanism of Action AMP activated protein kinase stimulants; Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 01 Nov 2015 Chong Kun Dang Pharmaceutical completes a pharmacokinetics phase I trial in Healthy volunteers in South Korea (PO) (NCT02648854)
  • 01 Oct 2015 Chong Kun Dang Pharmaceutical initiates a pharmacokinetics phase I trial in Healthy volunteers in South Korea (PO) (NCT02648854)
  • 01 Aug 2015 Chong Kun Dang completes a phase I trial in Healthy volunteers in South Korea (NCT02565368)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top